Iridian Asset Management LLC CT increased its position in Precigen, Inc. (NASDAQ:PGEN - Free Report) by 82.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,775,960 shares of the biotechnology company's stock after acquiring an additional 1,706,815 shares during the quarter. Iridian Asset Management LLC CT owned about 1.49% of Precigen worth $3,576,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the company. ClariVest Asset Management LLC lifted its position in Precigen by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 492,152 shares of the biotechnology company's stock valued at $778,000 after purchasing an additional 13,752 shares during the last quarter. SG Americas Securities LLC lifted its position in Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company's stock worth $43,000 after buying an additional 13,823 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in Precigen by 10.2% in the third quarter. Exchange Traded Concepts LLC now owns 167,496 shares of the biotechnology company's stock worth $159,000 after buying an additional 15,525 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Precigen by 40.7% during the second quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company's stock valued at $90,000 after acquiring an additional 16,486 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Precigen by 56.7% during the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company's stock worth $79,000 after acquiring an additional 18,097 shares in the last quarter. 33.51% of the stock is owned by institutional investors.
Precigen Price Performance
Shares of Precigen stock traded down $0.04 during trading on Thursday, hitting $0.79. 863,218 shares of the company's stock traded hands, compared to its average volume of 953,749. The business has a 50-day simple moving average of $0.96 and a 200-day simple moving average of $1.28. Precigen, Inc. has a 1 year low of $0.79 and a 1 year high of $1.93. The stock has a market capitalization of $199.23 million, a P/E ratio of -1.46 and a beta of 1.66.
Precigen (NASDAQ:PGEN - Get Free Report) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). Precigen had a negative return on equity of 90.99% and a negative net margin of 3,084.55%. The firm had revenue of $0.72 million for the quarter, compared to the consensus estimate of $1.28 million. On average, equities analysts predict that Precigen, Inc. will post -0.44 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
PGEN has been the topic of a number of analyst reports. HC Wainwright decreased their target price on shares of Precigen from $6.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday, August 15th. StockNews.com raised shares of Precigen to a "sell" rating in a research note on Thursday, August 1st. Finally, JMP Securities cut their price target on shares of Precigen from $14.00 to $7.00 and set a "market outperform" rating on the stock in a report on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $7.00.
View Our Latest Stock Report on PGEN
Insider Activity at Precigen
In related news, SVP Jeffrey Thomas Perez acquired 58,823 shares of the company's stock in a transaction on Friday, August 9th. The stock was acquired at an average price of $0.85 per share, with a total value of $49,999.55. Following the acquisition, the senior vice president now directly owns 743,097 shares of the company's stock, valued at approximately $631,632.45. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 44.90% of the stock is currently owned by corporate insiders.
Precigen Company Profile
(
Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Further Reading
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
